| Outcome |
Relative effect
(95% CI) |
Absolute effect
(95% CI)1 |
Certainty of the Evidence
(GRADE) |
Viral negative conversion
D7 |
Outcome not yet measured or reported
|
|
Clinical improvement
D28 |
RR: 1.03
(0.85 - 1.24) |
25 more per 1000
(from 123 fewer to 197 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Serious
Risk of bias downgraded by 1 level: some concerns regarding deviation from intended intervention, outcome measurement and selection of the reported results Inconsistency: Not serious Indirectness: Serious
single study from a single institution therefore results in this population might not be generalizable to other settings Imprecision: Serious
due to low number of participants
|
| 1 trials
Nourian A, 2020
90 participants
|
|
Sofosbuvir/ledipasvir
847 per 1,000
(699 - 1000) |
Standard care
822
per 1,000 |
|
Clinical improvement
D60 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above)
D28 |
Outcome not yet measured or reported
|
|
WHO progression score (level 7 or above)
D60 |
Outcome not yet measured or reported
|
|
All-cause mortality
D28 |
RR: 0.37
(0.03 - 4.30) |
33 fewer per 1000
(from 51 fewer to 175 more)
|
Very low certainty
Reasons to downgrade
Risk of bias: Serious
Risk of bias downgraded by 1 level: some concerns regarding deviations from intended intervention and selection of reported results Inconsistency: Serious
Inconsistency downgraded by 1 level: I²=:58% Indirectness: Not serious
Imprecision: Very serious
due to very wide confidence interval consistent with the possibility for benefit and the possibility for harm and low number of participants
|
| 2 trials
Nourian A, 2020; Elgohary M, 2021
340 participants
|
|
Sofosbuvir/ledipasvir
20 per 1,000
(2 - 228) |
Standard care
53
per 1,000 |
|
All-cause mortality
D60 |
Outcome not yet measured or reported
|
|
Adverse events
|
Outcome not yet measured or reported
|
|
Serious adverse events
|
Outcome not yet measured or reported
|
|
1The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI)
CI: Confidence interval; RR: Risk ratio
GRADE Working Group grades of evidence
High certainty: We are very confident that the true effect lies close to that of the estimate of the effect
Moderate certainty: We are moderately confident in the effect estimate: The true effect is likely to be close to the estimate of the effect, but there is a possibility that it is substantially different
Low certainty: Our confidence in the effect estimate is limited: The true effect may be substantially different from the estimate of the effect
Very low certainty: We have very little confidence in the effect estimate: The true effect is likely to be substantially different from the estimate of effect
